Shin Nippon Biomedical Laboratories Second Quarter 2025 Earnings: EPS: JP¥29.04 (vs JP¥38.27 in 2Q 2024)

Simply Wall St

November 08, 2024

Shin Nippon Biomedical Laboratories (TSE:2395) Second Quarter 2025 Results

Key Financial Results

Revenue: JP¥6.96b (up 14% from 2Q 2024).
Net income: JP¥1.21b (down 24% from 2Q 2024).
Profit margin: 17% (down from 26% in 2Q 2024). The decrease in margin was driven by higher expenses.
EPS: JP¥29.04 (down from JP¥38.27 in 2Q 2024).

earnings-and-revenue-growth — TSE:2395 Earnings and Revenue Growth November 8th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shin Nippon Biomedical Laboratories Earnings Insights

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in Asia.

Performance of the market in Japan.

The company's shares are up 17% from a week ago.

Risk Analysis

We should say that we've discovered 4 warning signs for Shin Nippon Biomedical Laboratories (2 don't sit too well with us!) that you should be aware of before investing here.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.